


## MC70

<b>Cat. No.:</b>	HY-113805		
<b>CAS No.:</b>	1031367-64-2		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>25</sub> NO <sub>3</sub>		
<b>Molecular Weight:</b>	375.46		
<b>Target:</b>	P-glycoprotein		
<b>Pathway:</b>	Membrane Transporter/Ion Channel		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 250 mg/mL (665.85 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.6634 mL	13.3170 mL	26.6340 mL
5 mM	0.5327 mL	2.6634 mL	5.3268 mL
10 mM	0.2663 mL	1.3317 mL	2.6634 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

MC70 is a potent and non-selective P-glycoprotein (P-gp) inhibitor with an EC<sub>50</sub> of 0.69 μM. MC70 is an ABC transporters inhibitor and anticancer agent. MC70 interacts with ABCB1, ABCG2 and ABCC1<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

EC50: 0.69 μM (P-glycoprotein)<sup>[1]</sup>

### REFERENCES

[1]. Stefano Guglielmo, et al. Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4'-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Ri

[2]. Amalia Azzariti, et al. MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. Eur J Pharmacol. 2011 Nov 16;670(1):74-84.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA